KZR — Kezar Life Sciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1645666 ·
Last close
$7.29
Market Cap
$53.86M
52W High
$7.55
52W Low
$6.08
ADV30
142,389
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -8,327,000 | -14,546,000 | 76,647,000 | 71,878,000 | 6,574,000 |
| Sep 2025 | 0 | — | -11,715,000 | -11,227,000 | 97,726,000 | 38,935,000 | 14,750,000 |
| Jun 2025 | 0 | — | -14,599,000 | -13,704,000 | 109,123,000 | 34,367,000 | 17,337,000 |
| Mar 2025 | 0 | — | -17,629,000 | -16,556,000 | 125,260,000 | 37,002,000 | 22,191,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,777,000
Investing CF
$92,463,000
Financing CF
$-10,585,000
CapEx
$-19,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.40
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-490,532,000
Inventory
—
Receivables
$1,997,000
ST Investments
$0
EBIT TTM
$-54,663,000
Pretax Income TTM
$-56,033,000
Interest Exp TTM
$1,370,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -52,270,000 | -56,033,000 | 76,647,000 | 6,574,000 | — | -51,777,000 |
| Dec 2024 | 0 | -89,135,000 | -83,736,000 | 144,682,000 | 27,766,000 | — | -74,212,000 |
| Dec 2023 | 7,000,000 | -105,237,000 | -101,870,000 | 221,235,000 | 33,665,000 | — | -81,645,000 |
| Dec 2022 | 0 | -71,162,000 | -68,239,000 | 299,568,000 | 29,696,000 | — | -58,846,000 |
TTM Snapshot
Revenues TTM
$2,237,000
NetIncome TTM
$-21,547,000
OpCashFlow TTM
$0
Assets (Latest)
$144,682,000
Forward EPS
$-4.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCYX | SCYNEXIS INC | $54.10M | $0.68 | — |
| MREO | Mereo BioPharma Group plc | $53.26M | $0.33 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $52.64M | $2.20 | — |
| IBO | IMPACT BIOMEDICAL INC. | $55.20M | $0.51 | — |
| HYPD | HYPERION DEFI, INC. | $56.08M | $3.70 | — |
News headlines (Yahoo Finance, 1h cache)
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
2026-05-19 12:30 · Yahoo
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
2026-03-30 12:00 · Yahoo
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
2026-03-12 13:00 · Yahoo
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
2026-01-09 11:01 · Yahoo
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
2026-01-05 17:00 · Yahoo
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
2025-11-12 21:01 · Yahoo
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
2025-11-07 12:01 · Yahoo
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
2025-10-16 20:05 · Yahoo
All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy
2025-09-17 16:00 · Yahoo
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
2025-08-28 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.